ArticleFrontiers in neurology2023
Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease.
Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Invasive therapies for Parkinson's disease: an adapted excerpt from the guidelines of the German Society of Neurology.Journal of neurology · 2025Pooled it
- Effects of Continuous Infusion Therapies on Non-Motor Symptoms in Advanced Parkinson's Disease: A Systematic Review.Brain sciences · 2026Review
- Exploring Preferences and Priorities in Advanced Parkinson's Disease: A Discrete Choice Experiment.Neurology and therapy · 2026Article
- Burden and disutility of sleep disturbance and early morning OFF symptoms in people with advancing Parkinson's disease: a vignette-based approach using the EQ-5D-5L.Journal of patient-reported outcomes · 2026Article
- Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sleep disturbances are commonly encountered in people with advanced Parkinson's disease (PD). In these stages, levodopa-carbidopa intestinal gel (LCIG) is recommended for improving motor symptoms, some non-motor dysfunctions, and quality of life in these patients. This study aimed to assess the effects of LCIG on sleep in PD in a longitudinal study. Study design: An open-label observational study in patients with advanced PD undergoing LCIG treatment was carried out. Measures and outcomes: In total, 10 consecutive advanced people with PD were evaluated at the baseline and after 6 months and 1 year, respectively, of LCIG infusion. Sleep parameters were assessed with several validated scales. We assessed the evolution of sleep parameters under LCIG infusion over time and the effects on sleep quality. Results: Significant improvement following LCIG was observed in PSQI total score ( Conclusion: LCIG infusion demonstrated beneficial effects on sleep parameters and sleep quality, which were constant over time for up to 12 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.